Overview

Safety Study of High Doses of Zinc in ALS Patients

Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety of Zinc given at 90mg/d in conjunction with 2mg/d of copper in ALS patients.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Phoenix Neurological Associates, LTD
Treatments:
Copper
Zinc